USP9YP26
associated omics dataQ-omics provides the consensus-scored USP9YP26 profile across patient tissues and cancer cell-line models. USP9YP26 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in ESCA.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP9YP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes USP9YP26 survival associations across molecular data types. USP9YP26 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP9YP26 RNA expression–survival associations across cancer types. High USP9YP26 expression shows unfavorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .035). Together, the overview and detailed table identify ESCA as the clearest survival context for USP9YP26 RNA expression.
